Juan W. Valle
YOU?
Author Swipe
View article: 320P First-line therapy (1L) of cisplatin/gemcitabine (CisGem) with pembrolizumab (pembro) in patients with advanced biliary tract cancer (aBTC): Open-label, single-arm phase II EORTC-1607-GITCG/ABC-09 intergroup study with translational research (TR)
320P First-line therapy (1L) of cisplatin/gemcitabine (CisGem) with pembrolizumab (pembro) in patients with advanced biliary tract cancer (aBTC): Open-label, single-arm phase II EORTC-1607-GITCG/ABC-09 intergroup study with translational research (TR) Open
View article: Differences in Language Used to Describe Racial Groups in Emergency Medicine Standardized Letter of Evaluation
Differences in Language Used to Describe Racial Groups in Emergency Medicine Standardized Letter of Evaluation Open
View article: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10—Precision Medicine)
Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10—Precision Medicine) Open
SAFIR-ABC10 is, to our knowledge, the first randomised, umbrella trial assessing the concept of precision medicine in ABC, the ideal setting for addressing this question with a high rate of targetable alterations.
View article: Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma
Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma Open
Background: Quantitative drug benefit–risk assessment (BRA) helps assess the magnitude of benefit and risk of new cancer therapies. This BRA aimed to summarize the evidence for the benefits and risks of ivosidenib versus placebo for the tr…
View article: Disparities in US public historic cancer mortality data: Advocacy for gastrointestinal cancers, tailored prevention measures, and the inclusion of oversea deaths. -Under-reporting of cancer deaths as sign of health disparity
Disparities in US public historic cancer mortality data: Advocacy for gastrointestinal cancers, tailored prevention measures, and the inclusion of oversea deaths. -Under-reporting of cancer deaths as sign of health disparity Open
Historically, data from US death certificates, available through the CDC’s WONDER database, have been used to highlight health disparities. The 5 year (2018-2022) underlying-cause-of-death data were analyzed for different race/ethnicity gr…
View article: Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study
Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study Open
Our study revealed substantial variation among oncologists in counseling on adjuvant chemotherapy after PDAC resection. This emphasizes the need for more patient involvement in decision-making and improving shared decision-making.
View article: Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial Open
PURPOSE The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survi…
View article: Screening and surveillance practices for Multiple Endocrine Neoplasia type 1‐related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence ( <scp>ENETS CoE</scp> )—An <scp>ENETS MEN1</scp> task force questionnaire study
Screening and surveillance practices for Multiple Endocrine Neoplasia type 1‐related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence ( <span>ENETS CoE</span> )—An <span>ENETS MEN1</span> task force questionnaire study Open
Multiple Endocrine Neoplasia type 1 (MEN1) Clinical Practice Guidelines (2012) are predominantly based on expert opinion due to limited available evidence at the time, leaving room for interpretation and variation in practices. Evidence on…
View article: Radioterapia coadjuvante no tratamento da hidrosadenite supurativa
Radioterapia coadjuvante no tratamento da hidrosadenite supurativa Open
Introdução: A hidrosadenite supurativa é uma doença inflamatória crônica, de origem infecciosa, que acomete as glândulas sudoríparas apócrinas. Os fatores associados ao aparecimento da patologia são variados e a etiologia ainda é incerta. …
View article: An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment
An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment Open
Pancreatic ductal adenocarcinoma continues to have a poor prognosis, although recent advances in neoadjuvant treatments (NATs) have provided some hope. Imaging assessment of suspected tumours can be challenging and requires a specific appr…
View article: Guidelines Development Group for the British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma
Guidelines Development Group for the British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma Open
View article: Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease
Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease Open
View article: Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer Open
The results support the use of futibatinib for treating people with advanced bile duct cancer. Based on the results of this study, futibatinib is now approved in the US, Europe, and Japan. Futibatinib is approved for treating adults with a…
View article: Corrigendum to “Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours” [Eur J Cancer 188 (2023) 39–48]
Corrigendum to “Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours” [Eur J Cancer 188 (2023) 39–48] Open
View article: Somatostatin Receptor Imaging with [<sup>18</sup>F]FET-βAG-TOCA PET/CT and [<sup>68</sup>Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study
Somatostatin Receptor Imaging with [<sup>18</sup>F]FET-βAG-TOCA PET/CT and [<sup>68</sup>Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study Open
There is a clinical need for 18F-labeled somatostatin analogs for the imaging of neuroendocrine tumors (NET), given the limitations of using [68Ga]Ga-DOTA-peptides, particularly with regard to widespread accessibility…
View article: Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies Open
View article: Salmonella pneumonia and empyema in a patient with end-stage liver disease
Salmonella pneumonia and empyema in a patient with end-stage liver disease Open
View article: PACT-UK (PAncreatic Cancer reporting Template–UK): a cross-specialty multi-institutional consensus panel development of a standardised radiological reporting proforma for pancreatic cancer
PACT-UK (PAncreatic Cancer reporting Template–UK): a cross-specialty multi-institutional consensus panel development of a standardised radiological reporting proforma for pancreatic cancer Open
Objective Appropriate staging of pancreatic cancer is essential to ensure patients are offered all treatment options. This multispecialty national collaborative consensus project aimed to develop a succinct radiological reporting template,…
View article: Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre
Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre Open
Advanced pancreatic cancer is associated with a poor prognosis, often less than 1 year. Honest prognosis discussions guide early community palliative care services input, facilitating timely advance care planning and improving quality of l…
View article: Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma
Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma Open
Extra-pulmonary poorly differentiated neuroendocrine carcinoma is rare, and evidence for treatment has been limited. In this article, the evidence behind the cytotoxic chemotherapy choices used for metastatic or unresectable EP-PD-NEC is r…
View article: Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy
Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy Open
View article: European Neuroendocrine Tumour Society ( <scp>ENETS</scp> ) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours
European Neuroendocrine Tumour Society ( <span>ENETS</span> ) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours Open
This ENETS guidance paper for well‐differentiated nonfunctioning pancreatic neuroendocrine tumours (NF‐Pan‐NET) has been developed by a multidisciplinary working group, and provides up‐to‐date and practical advice on the management of thes…
View article: British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma
British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma Open
These guidelines for the diagnosis and management of cholangiocarcinoma (CCA) were commissioned by the British Society of Gastroenterology liver section. The guideline writing committee included a multidisciplinary team of experts from var…
View article: Plain Language Summary of the TOPAZ-1 Study: Durvalumab and Chemotherapy for Advanced Biliary Tract Cancer
Plain Language Summary of the TOPAZ-1 Study: Durvalumab and Chemotherapy for Advanced Biliary Tract Cancer Open
Overall, these results support durvalumab and chemotherapy as a new treatment option for people with advanced BTCs. Based on the results of this study, durvalumab is now approved for the treatment of adults with advanced BTCs in combinatio…
View article: Corrigendum to “EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma” [J Hepatol (79) (2023) 181–208]
Corrigendum to “EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma” [J Hepatol (79) (2023) 181–208] Open
View article: Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma Open
The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for HCC and established immune …
View article: Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?
Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient? Open
For unresectable intrahepatic cholangiocarcinoma (iCC), different locoregional treatments (LRT) could be proposed to patients, including radiofrequency ablation (RFA) and microwave ablation (MWA), external beam radiotherapy (EBRT) or trans…
View article: Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trial
Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trial Open
View article: Patients Undergoing Systemic Anti-Cancer Therapy Who Require Surgical Intervention: What Surgeons Need to Know
Patients Undergoing Systemic Anti-Cancer Therapy Who Require Surgical Intervention: What Surgeons Need to Know Open
As part of routine cancer care, patients may undergo elective surgery with the aim of long-term cure. Some of these patients will receive systemic anti-cancer therapy (SACT) in the neoadjuvant and adjuvant settings. The majority of patient…
View article: Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials
Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials Open
Backgound and Aims: In advanced, liver-only intrahepatic cholangiocarcinoma (iCCA), selective internal radiation therapy (SIRT) has been suggested as promising in nonrandomized studies. We aimed to compare data from patients with advanced,…